Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.

@article{Gumbo2015ForecastingAO,
  title={Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.},
  author={Tawanda Gumbo and Jotam G. Pasipanodya and Klaus Romero and Debra L. Hanna and Eric L. Nuermberger},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2015},
  volume={61 Suppl 1},
  pages={
          S25-31
        }
}
  • T. Gumbo, J. Pasipanodya, E. Nuermberger
  • Published 15 August 2015
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
BACKGROUND The hollow fiber system model of tuberculosis (HFS-TB), in tandem with Monte Carlo experiments, represents a drug development tool (DDT) with the potential for use to develop tuberculosis treatment regimens. However, the predictive accuracy of the HFS-TB, or any other nonclinical DDT such as an animal model, has yet to be robustly evaluated. METHODS To avoid hindsight bias, a literature search was performed to identify clinical studies published at least 6 months after HFS-TB… 

Figures and Tables from this paper

Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
TLDR
The HFS-TB model is highly accurate at identifying optimal drug exposures, doses, and dosing schedules for use in the clinic and compared its quantitative output to that from clinical trials.
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
TLDR
The HFS-TB model offers the ability to perform PK/PD studies including humanlike drug exposures, to identify bactericidal and sterilizing effect rates, and to identify exposures associated with suppression of drug resistance.
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
  • K. Romero, R. Clay, D. Hanna
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2015
The first nonclinical drug development tool (DDT) advanced by the Critical Path to TB Drug Regimens (CPTR) Initiative through a regulatory review process has been endorsed by leading global
Quantitative assessment of the activity of antituberculosis drugs and regimens
TLDR
Methods incorporating data generated from multiple sources such as in vitro and clinical studies, and their potential to provide better estimates of pharmacokinetic/pharmacodynamic (PK/PD) targets, are discussed.
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
TLDR
Gatifloxacin doses of 800 mg/day and 1200 mg/ day are recommended for pulmonary and meningeal MDR-TB treatment, respectively.
Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse
TLDR
A new method combining mathematical modeling and machine learning is proposed to derive early (within 2 months) effective predictive biomarkers from bacterial load slopes for tuberculosis long term treatment outcomes, thereby accurately predicting treatment failure and success.
Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
TLDR
The optimal exposures and kill rates identified for log-phase M. tuberculosis will be optimal even for semidormant bacilli, and the EC90 is the dosing target for intermittent therapy that optimizes cure in TB programs for MDR-TB patients.
A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting
TLDR
The stepwise pharmacokinetics/pharmacodynamics approach provides a scientific rationale and a strategy for achieving short-course chemotherapy for pulmonary MAC disease within a few years.
Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing
TLDR
An ertapenem dosage of 2 g once daily is the most suitable to be tested in a phase II study of sterilizing effect in MDR-TB patients, and the doses and schedule that would achieve or exceed a %TMIC of ≥40% are identified.
...
...

References

SHOWING 1-10 OF 55 REFERENCES
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
TLDR
The HFS-TB model offers the ability to perform PK/PD studies including humanlike drug exposures, to identify bactericidal and sterilizing effect rates, and to identify exposures associated with suppression of drug resistance.
Serum drug concentrations predictive of pulmonary tuberculosis outcomes.
TLDR
Low drug AUCs are predictive of clinical outcomes in tuberculosis patients, and low rifampin and isoniazid peak and AUC concentrations preceded all cases of acquired drug resistance.
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.
TLDR
Pharmacokinetic variability to a single drug in the regimen is significantly associated with failure of therapy and ADR in patients, suggesting that individualized dosing for tuberculosis may be more effective than standardized dosing, which is prescribed in directly observed therapy programs.
Nonclinical models for antituberculosis drug development: a landscape analysis.
TLDR
There is a need for formal quantitative analyses of how well DDTs forecast clinical outcomes, and no single nonclinical in vitro or animal model recapitulates all aspects of human tuberculosis.
Redefining Multidrug-Resistant Tuberculosis Based on Clinical Response to Combination Therapy
TLDR
Rifampin and isoniazid MICs improved the predictive capacity of the primary decision node by 20 and 17%, respectively, for these 36 patients, which is similar to those derived in clinical trial simulations.
Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs
TLDR
The overall results suggest that the pulmonary concentrations obtained with the standard RIF dose are too low in most subjects, and supports the need to evaluate higher doses of RIF for the treatment of patients with tuberculosis.
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience
TLDR
TB patients treated at the Tuberculosis Centre Beatrixoord, University Medical Centre Groningen receiving MFX 400 mg once daily as part of their TB treatment between January 1 2006 and January 1 2009 were reviewed.
Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
TLDR
Preclinical PK/PD studies are essential value added in the development of antituberculosis agents when properly designed exposure-effect and dose-fractionation studies have been performed in preclinical models.
Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous Meningitis
TLDR
Univariable and multivariable analyses of fluoroquinolone exposure against a range of different treatment responses revealed worse outcomes among patients with lower and higher plasma and CSF exposures than for patients with intermediate exposures (a U-shaped exposure-response).
...
...